Unlike its first U.K. reimbursement negotiations, Roche’s HER2 antibody-drug conjugate sailed through a new NHS funding review that now puts it in line for earlier breast cancer use. Kadcyla has won ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results